SAN CLEMENTE, Calif., Aug. 12 /PRNewswire/ -- Terry A. Fuller, Ph.D., considered one of the world's most renowned experts in the field of minimally invasive surgical laser technology, has been named the first Chairman of the newly founded Scientific Advisory Board for BIOLASE Technology, Inc. (Nasdaq: BLTI - news), a California-based company which designs, manufactures and markets laser-based systems for use in cosmetic surgery, dermatology and dentistry.
''We are proud and very excited that Dr. Fuller has agreed to accept this post. His extensive knowledge of surgical laser technology and expertise in delivery systems will make him invaluable to us. We greatly welcome him aboard,'' said BIOLASE Chairman of the Board, Federico Pignatelli, in his announcement. He added that Dr. Fuller's appointment was ''the first of several steps the company is taking to further strengthen and expand BIOLASE management team.''
As Chairman of the Scientific Advisory Board, Dr. Fuller will be instrumental in developing both the Board and its specific goals to assist BIOLASE. Additionally, Dr. Fuller periodically may be assigned to work on certain special projects for the company.
''Dr. Fuller joins BIOLASE at a very exciting point of our history. I anticipate applying his vast experience, both technically and managerially, in several areas,'' added Donald A. LaPoint, President and CEO of BIOLASE.
Dr. Fuller began a close association with the company earlier this year when BIOLASE initiated successful negotiations to acquire the assets of Laser Skin Toner, Inc., a research and development firm he co-founded and served as President and CEO. Under his leadership, Laser Skin Toner, Inc. designed, built and clinically evaluated disposable products for non-invasive surgical treatment of skin wrinkles and stretch marks.
For seven years prior to founding Laser Skin Toner, Inc., Dr. Fuller was Chief Operating Officer, Executive Vice President and Director of the Montgomeryville, Pennsylvania-based Surgical Laser Technologies, Inc., a small, publicly held corporation which is a worldwide leader in development, manufacturing, marketing and sales of minimally invasive surgical laser systems and consumable products. Prior to that appointment, he was Vice President of Research and Development, and Operations with a subsidiary of Johnson & Johnson, Site Microsurgical Corporation.
Dr. Fuller began his long affiliation with laser technology in 1974 as Director and Chairman of the Laser Surgery & Photobiology Institute at Sinai Hospital in Detroit. He helped to form multi-specialty outpatient surgical centers as a adjunct to hospital-based surgery. The following year, he added to his duties the role of President of MedLase, Inc. and Fuller Research Corporation where he spearheaded the design and sales of the Ruby and CO2 lasers.
A native of Philadelphia, Dr. Fuller was educated at Worcester Polytechnic Institute and Clark University. He attended the University of Massachusetts Medical School and holds a Ph.D. in Biomedical Engineering/Biophysics. He currently holds the position of Adjunct Instructor at Jefferson Medical College.
Dr. Fuller is the author of nine U.S. patents, over 50 books and peer review articles, and holds numerous awards from the American Medical Association and others for his contributions to surgery and medical devices. He currently resides in Rydal, Pennsylvania with his wife, Zena, and two children.
The matters discussed in this news release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. |
